Effects of CYP1A2 on disposition of 2,3,7,8-tetrachlorodibenzo-p-dioxin, 2,3,4,7,8-pentachlorodibenzofuran, and 2,2′,4,4′,5,5′-hexachlorobiphenyl in CYP1A2 knockout and parental (C57BL/6N and 129/Sv) strains of mice

被引:91
作者
Diliberto, JJ
Burgin, DE
Birnbaum, LS
机构
[1] US EPA, Natl Hlth Effects & Environm Res Lab, Div Environm Toxicol, PKB, Res Triangle Pk, NC 27711 USA
[2] Univ N Carolina, Curriculum Toxicol, Chapel Hill, NC 27599 USA
关键词
D O I
10.1006/taap.1999.8720
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
TCDD is the prototype and most potent member of the highly lipophilic polyhalogenated aromatic hydrocarbons (PHAHs), which are persistent and ubiquitous environmental contaminants. In both acute and subchronic animal studies, there is a specific accumulation of TCDD in liver greater than in adipose tissue. The inducible hepatic binding protein responsible for this hepatic sequestration of TCDD and its congeners has been shown by our laboratory to be CYP1A2 (J. J. Diliberto, D. Burgin, and L. S. Birnbaum, 1997, Biochem. Biophys. Res. Commun. 236, 431-433). The present study was conducted using knockout (KO) mice lacking expression of CYP1A2 (CYP1A2-/-) in order to investigate the role of CYP1A2 gene on the disposition of TCDD, 4-PeCDF (a dioxin-like PHAH), and PCB 153 (a nondiosin-like PCB) in KO (CYP1A2-/-) mice and age-matched parental mice strains (C57BL/6N: CYP1A2+/+, Ah(b/b) and 129/Sv: CYP1A2+/+, Ah(d/d)). Mice were dosed (25 mu g [H-3]TCDD/kg 300 mu g [C-14]4-PeCDF/kg, or 35.8 mg [C-14]PCB 153/kg bw in a corn oil vehicle) orally and terminated after 4 days. Residues of administered compounds in collected tissues and daily excreta were quantitated using H-3 or C-14 activity. Results demonstrated differential effects in disposition for the various treatments within the three genetically different groups of mice. In KO mice, TCDD, 4-PeCDF, and PCB 153 had very little hepatic localization of chemical, and the major depot was adipose tissue. In contrast, parental strains demonstrated hepatic sequestration of TCDD and 4-PeCDF, whereas disposition of PCB 153 in parental strains was similar to that in KO mice. Another difference between KO mice and parental strains was the enhanced urinary excretion of 4-PeCDF. This study demonstrates the importance of CYP1A2 in pharmacokinetic behavior and mechanistic issues for TCDD and related compounds. (C) 1999 Academic Press.
引用
收藏
页码:52 / 64
页数:13
相关论文
共 75 条
[1]   PHARMACOKINETICS AND BIOLOGICAL-ACTIVITY OF 2,3,7,8-TETRACHLORODIBENZO-PARA-DIOXIN .1. DOSE-DEPENDENT TISSUE DISTRIBUTION AND INDUCTION OF HEPATIC ETHOXYRESORUFIN O-DEETHYLASE IN RATS FOLLOWING A SINGLE INJECTION [J].
ABRAHAM, K ;
KROWKE, R ;
NEUBERT, D .
ARCHIVES OF TOXICOLOGY, 1988, 62 (05) :359-368
[2]   TOXIC EQUIVALENCY FACTORS FOR DIOXIN-LIKE PCBS - REPORT ON A WHO-ECEH AND IPCS CONSULTATION, DECEMBER 1993 [J].
AHLBORG, UG ;
BECKING, GC ;
BIRNBAUM, LS ;
BROUWER, A ;
DERKS, HJGM ;
FEELEY, M ;
GOLOR, G ;
HANBERG, A ;
LARSEN, JC ;
LIEM, AKD ;
SAFE, SH ;
SCHLATTER, C ;
WAERN, F ;
YOUNES, M ;
YRJANHEIKKI, E .
CHEMOSPHERE, 1994, 28 (06) :1049-1067
[3]  
BATRA R, 1994, TOXICOLOGIST, V14, P408
[4]   EFFECT OF DIETARY AROCLOR-1254 EXPOSURE ON LUNG AND KIDNEY CYTOCHROMES P450 IN FEMALE RATS - EVIDENCE FOR P4501A2 EXPRESSION IN KIDNEY [J].
BEEBE, LE ;
FORNWALD, LW ;
ALWORTH, WL ;
DRAGNEV, KH ;
LUBET, RA .
CHEMICO-BIOLOGICAL INTERACTIONS, 1995, 97 (03) :215-227
[5]  
BERTHOU F, 1991, DRUG METAB DISPOS, V19, P561
[6]   THE MECHANISM OF DIOXIN TOXICITY - RELATIONSHIP TO RISK ASSESSMENT [J].
BIRNBAUM, LS .
ENVIRONMENTAL HEALTH PERSPECTIVES, 1994, 102 :157-167
[7]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[8]   DISPOSITION AND EXCRETION OF 2,3,4,7,8-PENTACHLORODIBENZOFURAN IN THE RAT [J].
BREWSTER, DW ;
BIRNBAUM, LS .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1987, 90 (02) :243-252
[9]   DETERMINATION OF CYP1A2 AND NAT2 PHENOTYPES IN HUMAN-POPULATIONS BY ANALYSIS OF CAFFEINE URINARY METABOLITES [J].
BUTLER, MA ;
LANG, NP ;
YOUNG, JF ;
CAPORASO, NE ;
VINEIS, P ;
HAYES, RB ;
TEITEL, CH ;
MASSENGILL, JP ;
LAWSEN, MF ;
KADLUBAR, FF .
PHARMACOGENETICS, 1992, 2 (03) :116-127
[10]  
BUTLER MA, 1989, CANCER RES, V49, P25